166 related articles for article (PubMed ID: 38553800)
1. The humoral immune response to the BNT 162B2 vaccine in pediatrics on renal replacement therapy.
Alshami A; Bahbah H; Al Attas R; Aldokhi F; Azzam A
Pediatr Transplant; 2024 May; 28(3):e14712. PubMed ID: 38553800
[TBL] [Abstract][Full Text] [Related]
2. Humoral immunity to SARS-CoV-2 in kidney transplant recipients and dialysis patients: IgA and IgG patterns unraveled after SARS-CoV-2 infection and vaccination.
De Bouver C; Bouziotis J; Wijtvliet VPWM; Ariën KK; Mariën J; Heyndrickx L; Couttenye MM; de Fijter HJW; Mestrez F; Treille S; Mat O; Collart F; Allard SD; Vingerhoets L; Moons P; Abramowicz D; De Winter BY; Pipeleers L; Wissing KM; Ledeganck KJ
Virol J; 2024 Jun; 21(1):138. PubMed ID: 38872127
[TBL] [Abstract][Full Text] [Related]
3. Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients.
Danthu C; Hantz S; Dahlem A; Duval M; Ba B; Guibbert M; El Ouafi Z; Ponsard S; Berrahal I; Achard JM; Bocquentin F; Allot V; Rerolle JP; Alain S; Touré F
J Am Soc Nephrol; 2021 Sep; 32(9):2153-2158. PubMed ID: 34135083
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the safety and immunogenicity of the BNT-162b2 vaccine and the ChAdOx1 vaccine for solid organ transplant recipients: a prospective study.
Ajlan AA; Ali T; Aleid H; Almeshari K; DeVol E; Alkaff MA; Fajji L; Alali A; Halabi D; Althuwaidi S; Alghamdi S; Ullah A; Alrajhi A; Bzeizi K; Almaghrabi R; Marquez KAH; Elmikkaoui B; Albogumi E; Aldakhil H; Al-Awwami M; Broering DC
BMC Infect Dis; 2022 Oct; 22(1):786. PubMed ID: 36229772
[TBL] [Abstract][Full Text] [Related]
5. Humoral immunogenicity and tolerability of heterologous ChAd/BNT compared with homologous BNT/BNT and ChAd/ChAd SARS-CoV-2 vaccination in hemodialysis patients : A multicenter prospective observational study.
Haase M; Lesny P; Anderson M; Cloherty G; Stec M; Haase-Fielitz A; Haarhaus M; Santos-Araújo C; Veiga PM; Macario F
J Nephrol; 2022 Jun; 35(5):1467-1478. PubMed ID: 35084719
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 Infection-and mRNA Vaccine-induced Humoral Immunity among Schoolchildren in Hawassa, Ethiopia.
Merid Y; Tekleselasie W; Tesfaye E; Gadisa A; Fentahun D; Abate A; Alemu A; Mihret A; Mulu A; Gelanew T
Front Immunol; 2023; 14():1163688. PubMed ID: 37398668
[TBL] [Abstract][Full Text] [Related]
7. Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.
Liu X; Munro APS; Wright A; Feng S; Janani L; Aley PK; Babbage G; Baker J; Baxter D; Bawa T; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Fox L; Qureshi E; Goodman AL; Green CA; Haughney J; Hicks A; Jones CE; Kanji N; van der Klaauw AA; Libri V; Llewelyn MJ; Mansfield R; Maallah M; McGregor AC; Minassian AM; Moore P; Mughal M; Mujadidi YF; Belhadef HT; Holliday K; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Saralaya D; Sharma S; Sheridan R; Stokes M; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Lambe T; Nguyen-Van-Tam JS; Cornelius V; Snape MD; Faust SN;
J Infect; 2023 Jul; 87(1):18-26. PubMed ID: 37085049
[TBL] [Abstract][Full Text] [Related]
8. Humoral and cellular immune response to SARS-CoV-2 mRNA BNT162b2 vaccine in pediatric kidney transplant recipients compared with dialysis patients and healthy children.
Gulmez R; Ozbey D; Agbas A; Aksu B; Yildiz N; Uckardes D; Saygili S; Yilmaz EK; Yildirim ZY; Tasdemir M; Kiykim A; Cokugras H; Canpolat N; Nayir A; Kocazeybek B; Caliskan S
Pediatr Nephrol; 2023 Jul; 38(7):2199-2208. PubMed ID: 36459243
[TBL] [Abstract][Full Text] [Related]
9. Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients.
Schramm R; Costard-Jäckle A; Rivinius R; Fischer B; Müller B; Boeken U; Haneya A; Provaznik Z; Knabbe C; Gummert J
Clin Res Cardiol; 2021 Aug; 110(8):1142-1149. PubMed ID: 34241676
[TBL] [Abstract][Full Text] [Related]
10. Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months.
Hsu CM; Weiner DE; Manley HJ; Aweh GN; Ladik V; Frament J; Miskulin D; Argyropoulos C; Abreo K; Chin A; Gladish R; Salman L; Johnson D; Lacson EK
Clin J Am Soc Nephrol; 2022 Mar; 17(3):403-413. PubMed ID: 35144972
[TBL] [Abstract][Full Text] [Related]
11. Humoral Response After SARS-CoV-2 Vaccination in Kidney Transplant Recipients: Role of Immunosuppression Therapy.
López V; Polo C; Schuldt R; Vázquez T; Gutiérrez-Vílchez E; Moliz C; Hernández D
Transplant Proc; 2022 Nov; 54(9):2454-2456. PubMed ID: 36273957
[TBL] [Abstract][Full Text] [Related]
12. Insufficient response to mRNA SARS-CoV-2 vaccine and high incidence of severe COVID-19 in kidney transplant recipients during pandemic.
Reischig T; Kacer M; Vlas T; Drenko P; Kielberger L; Machova J; Topolcan O; Kucera R; Kormunda S
Am J Transplant; 2022 Mar; 22(3):801-812. PubMed ID: 34860470
[TBL] [Abstract][Full Text] [Related]
13. Early humoral immune response to two doses of severe acute respiratory syndrome coronavirus 2 vaccine in a diverse group of solid organ transplant candidates and recipients.
Huang HJ; Yi SG; Mobley CM; Saharia A; Bhimaraj A; Moore LW; Kloc M; Adrogue HE; Graviss EA; Nguyen DT; Eagar TN; Jones SL; Ankoma-Sey V; MacGillivray TE; Knight RJ; Gaber AO; Ghobrial RM
Clin Transplant; 2022 May; 36(5):e14600. PubMed ID: 35083796
[TBL] [Abstract][Full Text] [Related]
14. [Humoral immunity against SARS-CoV-2 in workers of social health care centers of Castilla y León after vaccination with the BNT162b2 mRNA vaccine from Pfizer/Biontech.].
Casas Fischer R
Rev Esp Salud Publica; 2021 Oct; 95():. PubMed ID: 34690347
[TBL] [Abstract][Full Text] [Related]
15. Humoral and cellular response after BNT162b2 vaccine booster in hemodialysis patients and kidney transplant recipients.
De Cagna MR; Colucci V; Di Maggio A; Notaristefano N; Cianciotta F; Danza K; Salvatore F; Santoniccolo A; Lanzillotta SG; Perniola MA; Marangi AL; Morrone LFP; Tampoia M
Clin Exp Nephrol; 2023 May; 27(5):445-453. PubMed ID: 36795176
[TBL] [Abstract][Full Text] [Related]
16. Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.
Liu X; Munro APS; Feng S; Janani L; Aley PK; Babbage G; Baxter D; Bula M; Cathie K; Chatterjee K; Dejnirattisai W; Dodd K; Enever Y; Qureshi E; Goodman AL; Green CA; Harndahl L; Haughney J; Hicks A; van der Klaauw AA; Kwok J; Libri V; Llewelyn MJ; McGregor AC; Minassian AM; Moore P; Mughal M; Mujadidi YF; Holliday K; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Serafimova T; Saralaya D; Screaton GR; Sharma S; Sheridan R; Sturdy A; Supasa P; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Lambe T; Nguyen-Van-Tam JS; Cornelius V; Snape MD; Faust SN;
J Infect; 2022 Jun; 84(6):795-813. PubMed ID: 35405168
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of one and two booster doses of SARS-CoV-2 mRNA vaccines in kidney transplant recipients: A randomized clinical trial.
Drenko P; Kacer M; Kielberger L; Vlas T; Topolcan O; Kucera R; Reischig T
Transpl Infect Dis; 2023 Oct; 25(5):e14150. PubMed ID: 37724748
[TBL] [Abstract][Full Text] [Related]
18. Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity.
Bowman KA; Stein D; Shin S; Ferbas KG; Tobin NH; Mann C; Fischinger S; Ollmann Saphire E; Lauffenburger D; Rimoin AW; Aldrovandi G; Alter G
mBio; 2022 Oct; 13(5):e0164722. PubMed ID: 36000735
[TBL] [Abstract][Full Text] [Related]
19. Seroconversion after SARS-CoV-2 vaccination is protective against severe COVID-19 disease in heart transplant recipients.
Kugler S; Vári DK; Veres DS; Király Á; Teszák T; Parázs N; Tarjányi Z; Drobni Z; Szakál-Tóth Z; Prinz G; Miheller P; Merkely B; Sax B
Immun Inflamm Dis; 2023 Nov; 11(11):e1086. PubMed ID: 38018598
[TBL] [Abstract][Full Text] [Related]
20. Impaired humoral and cellular response to primary COVID-19 vaccination in patients less than 2 years after allogeneic bone marrow transplant.
Murray SM; Barbanti M; Campbell C; Brown A; Chen L; Dhanapal J; Tseu B; Pervaiz O; Peters L; Springett S; Danby R; Adele S; Phillips E; Malone T; Amini A; Stafford L; Deeks AS; Dunachie S; Klenerman P; Peniket A; Barnes E; Kesavan M
Br J Haematol; 2022 Aug; 198(4):668-679. PubMed ID: 35655410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
